WO2012025925A1 - Procédés d'amélioration de la transplantation en utilisant des sdf-1alpha - Google Patents

Procédés d'amélioration de la transplantation en utilisant des sdf-1alpha Download PDF

Info

Publication number
WO2012025925A1
WO2012025925A1 PCT/IL2011/000683 IL2011000683W WO2012025925A1 WO 2012025925 A1 WO2012025925 A1 WO 2012025925A1 IL 2011000683 W IL2011000683 W IL 2011000683W WO 2012025925 A1 WO2012025925 A1 WO 2012025925A1
Authority
WO
WIPO (PCT)
Prior art keywords
tissue
cell
fat
subject
sdf
Prior art date
Application number
PCT/IL2011/000683
Other languages
English (en)
Inventor
Saher Hamed
Yehuda Ullmann
Benjamin Brenner
Ariel Roguin
Original Assignee
Rappaport Family Institute For Research In The Medical Sciences
Fund For Medical Research Development Of Infrastructure And Health Services - At Rambam Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rappaport Family Institute For Research In The Medical Sciences, Fund For Medical Research Development Of Infrastructure And Health Services - At Rambam Medical Center filed Critical Rappaport Family Institute For Research In The Medical Sciences
Publication of WO2012025925A1 publication Critical patent/WO2012025925A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé d'amélioration de la transplantation d'une cellule ou d'un tissu ou d'une greffe d'organe chez un sujet le nécessitant. Le procédé comprend l'administration à un sujet qui a subi une transplantation de cellule ou de tissu ou une greffe d'organe d'une quantité thérapeutiquement efficace de SDF-1alpha, améliorant ainsi la transplantation de la cellule ou du tissu ou la greffe d'organe chez le sujet.
PCT/IL2011/000683 2010-08-24 2011-08-24 Procédés d'amélioration de la transplantation en utilisant des sdf-1alpha WO2012025925A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37627310P 2010-08-24 2010-08-24
US61/376,273 2010-08-24

Publications (1)

Publication Number Publication Date
WO2012025925A1 true WO2012025925A1 (fr) 2012-03-01

Family

ID=44773103

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2011/000683 WO2012025925A1 (fr) 2010-08-24 2011-08-24 Procédés d'amélioration de la transplantation en utilisant des sdf-1alpha

Country Status (1)

Country Link
WO (1) WO2012025925A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016048105A1 (fr) * 2014-09-26 2016-03-31 주식회사 바이로메드 Composition pour la prévention ou le traitement des maladies vasculaires périphériques utilisant le facteur de croissance des hépatocytes et le facteur 1α dérivé des cellules stromales
WO2019070538A1 (fr) * 2017-10-03 2019-04-11 Wallkill BioPharma, Inc. Traitement du diabète avec des cellules bêta génétiquement modifiées
US10639351B2 (en) 2013-10-22 2020-05-05 Helixmith Co., Ltd. Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor
US11981928B2 (en) 2018-09-28 2024-05-14 Sdf Biopharma Inc. Methods for reducing elevated glucose levels

Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3791932A (en) 1971-02-10 1974-02-12 Akzona Inc Process for the demonstration and determination of reaction components having specific binding affinity for each other
US3839153A (en) 1970-12-28 1974-10-01 Akzona Inc Process for the detection and determination of specific binding proteins and their corresponding bindable substances
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3850752A (en) 1970-11-10 1974-11-26 Akzona Inc Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
US3879262A (en) 1972-05-11 1975-04-22 Akzona Inc Detection and determination of haptens
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
WO2000006704A2 (fr) * 1998-07-27 2000-02-10 Yeda Research And Development Co. Ltd. Composition a base de cellules hematopoietiques, a utiliser dans la transplantation
US20050136042A1 (en) 2003-08-12 2005-06-23 Betz Oliver B. Methods and compositions for tissue repair
WO2006032075A1 (fr) * 2004-09-24 2006-03-30 Angioblast Systems, Inc. Procédé d'accroissement de la prolifération et/ou de la survie de cellules précurseurs mésenchymateuses (mpc)
EP1726311A2 (fr) * 2001-12-06 2006-11-29 Yeda Research and development co. Ltd., an Israeli Company Migration de cellules hématopoiétiques et de cellules précurseurs vers le foie
US20080019434A1 (en) 2005-03-01 2008-01-24 Qualcomm Incorporated Method and apparatus for interference cancellation in a wireless communications system
WO2008096359A2 (fr) * 2007-02-08 2008-08-14 Rappaport Family Institute For Research In The Medical Sciences Agents pour le traitement de la sclérose en plaques et leurs procédés d'utilisation
WO2008121719A1 (fr) * 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Procédé de traitement des troubles ischémiques

Patent Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3850752A (en) 1970-11-10 1974-11-26 Akzona Inc Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically
US3839153A (en) 1970-12-28 1974-10-01 Akzona Inc Process for the detection and determination of specific binding proteins and their corresponding bindable substances
US3791932A (en) 1971-02-10 1974-02-12 Akzona Inc Process for the demonstration and determination of reaction components having specific binding affinity for each other
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
US3879262A (en) 1972-05-11 1975-04-22 Akzona Inc Detection and determination of haptens
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683202B1 (fr) 1985-03-28 1990-11-27 Cetus Corp
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
WO2000006704A2 (fr) * 1998-07-27 2000-02-10 Yeda Research And Development Co. Ltd. Composition a base de cellules hematopoietiques, a utiliser dans la transplantation
EP1726311A2 (fr) * 2001-12-06 2006-11-29 Yeda Research and development co. Ltd., an Israeli Company Migration de cellules hématopoiétiques et de cellules précurseurs vers le foie
US20100166717A1 (en) 2002-08-22 2010-07-01 Penn Marc S Method of treating ischemic disorders
US20050136042A1 (en) 2003-08-12 2005-06-23 Betz Oliver B. Methods and compositions for tissue repair
WO2006032075A1 (fr) * 2004-09-24 2006-03-30 Angioblast Systems, Inc. Procédé d'accroissement de la prolifération et/ou de la survie de cellules précurseurs mésenchymateuses (mpc)
US20080019434A1 (en) 2005-03-01 2008-01-24 Qualcomm Incorporated Method and apparatus for interference cancellation in a wireless communications system
WO2008096359A2 (fr) * 2007-02-08 2008-08-14 Rappaport Family Institute For Research In The Medical Sciences Agents pour le traitement de la sclérose en plaques et leurs procédés d'utilisation
WO2008121719A1 (fr) * 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Procédé de traitement des troubles ischémiques

Non-Patent Citations (61)

* Cited by examiner, † Cited by third party
Title
"Animal Cell Culture", 1986
"Basic and Clinical Immunology", 1994, APPLETON & LANGE
"Cell Biology: A Laboratory Handbook", vol. I-III, 1994
"Current Protocols in Immunology", vol. I-III, 1994
"Current Protocols in Molecular Biology", vol. I-III, 1994
"Genome Analysis: A Laboratory Manual Series", vol. 1-4, 1998, COLD SPRING HARBOR LABORATORY PRESS
"Immobilized Cells and Enzymes", 1986, IRL PRESS
"Methods in Enzymology", vol. 1-317, ACADEMIC PRESS
"Nucleic Acid Hybridization", 1985
"Oligonucleotide Synthesis", 1984
"PCR Protocols: A Guide To Methods And Applications", 1990, ACADEMIC PRESS
"Remington's Pharmaceutical Sciences", MACK PUBLISHING CO.
"Selected Methods in Cellular Immunology", 1980, W. H. FREEMAN AND CO.
"Transcription and Translation", 1984
ASSMUS B ET AL., CIRCULATION, vol. 106, no. 24, 2002, pages 3009 - 17
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1989, JOHN WILEY AND SONS
AYHAN M. ET AL., AESTHETIC PLAST SURG, vol. 25, 2001, pages 338 - 342
CANAPLE L. ET AL.: "Improving cell encapsulation through size control", J BIOMATER SCI POLYM ED., vol. 13, 2002, pages 783 - 96
CHANG TM, PRAKASH S.: "Procedures for microencapsulation of enzymes, cells and genetically engineered microorganisms", MOL BIOTECHNOL., vol. 17, 2001, pages 249 - 60
CHIA, S.M. ET AL.: "Multi-layered microcapsules for cell encapsulation", BIOMATERIALS, vol. 23, 2002, pages 849 - 56, XP004322709, DOI: doi:10.1016/S0142-9612(01)00191-0
DANTAL J. ET AL., LANCET, vol. 351, 1998, pages 623
DESAI, T.A.: "Microfabrication technology for pancreatic cell encapsulation", EXPERT OPIN BIOL THER., vol. 2, 2002, pages 633 - 46
DI ROCCO GIULIANA ET AL: "Enhanced healing of diabetic wounds by topical administration of adipose tissue-derived stromal cells overexpressing stromal-derived factor-1: biodistribution and engraftment analysis by bioluminescent imaging.", STEM CELLS INTERNATIONAL, vol. 2011, 304562, 2010, pages 1 - 11, XP002666787, ISSN: 1687-9678 *
ELMADBOUH I ET AL: "Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 42, no. 4, 1 April 2007 (2007-04-01), ACADEMIC PRESS, GB, pages 792 - 803, XP002643111, ISSN: 0022-2828, [retrieved on 20070208], DOI: 10.1016/J.YJMCC.2007.02.001 *
FINGL ET AL.: "The Pharmacological Basis of Therapeutics", 1975, pages: 1
GOLDSTEIN LJ ET AL., STEM CELLS, vol. 24, no. 10, 2006, pages 2309 - 18
H. CHENG ET AL: "Combinatorial treatment of bone marrow stem cells and stromal cell-derived factor 1 improves glycemia and insulin production in diabetic mice", MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 345, no. 1-2, 1 October 2011 (2011-10-01), pages 88 - 96, XP055014972, ISSN: 0303-7207, DOI: 10.1016/j.mce.2011.07.024 *
H. E. BROXMEYER: "Stromal cell-derived factor-1/CXCL12 directly enhances survival/antiapoptosis of myeloid progenitor cells through CXCR4 and Galphai proteins and enhances engraftment of competitive, repopulating stem cells", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 73, no. 5, 1 May 2003 (2003-05-01), pages 630 - 638, XP055015092, ISSN: 0741-5400, DOI: 10.1189/jlb.1002495 *
HANTO DW., ANNU REV MED., vol. 46, 1995, pages 381
HIASA K. ET AL., CIRCULATION, vol. 109, no. 20, 2004, pages 2454 - 61
HIGGINS RM. ET AL., LANCET, vol. 348, 1996, pages 1208
JIAN-XING YU ET AL: "Combination of stromal-derived factor-1[alpha] and vascular endothelial growth factor gene-modified endothelial progenitor cells is more effective for ischemic neovascularization", JOURNAL OF VASCULAR SURGERY, vol. 50, no. 3, 1 September 2009 (2009-09-01), pages 608 - 616, XP055014974, ISSN: 0741-5214, DOI: 10.1016/j.jvs.2009.05.049 *
KIRKPATRICK CH., ROWLANDS DT JR., JAMA, vol. 268, 1992, pages 2952
LAPIDOT ET AL., BLOOD, vol. 106, no. 6, 2005, pages 1901 - 10
LU F ET AL., PLAST RECONSTR SURG, vol. 124, 2009, pages 1437 - 1446
LU MZ ET AL.: "A novel cell encapsulation method using photosensitive poly(allylamine alpha- cyanocinnamylideneacetate", J MICROENCAPSUL., vol. 17, 2000, pages 245 - 51
LU MZ ET AL.: "Cell encapsulation with alginate and alpha- phenoxycinnamylidene-acetylated poly(allylamine", BIOTECHNOL BIOENG., vol. 70, 2000, pages 479 - 83, XP008025769, DOI: doi:10.1002/1097-0290(20001205)70:5<479::AID-BIT1>3.0.CO;2-E
MARSHAK ET AL.: "Strategies for Protein Purification and Characterization - A Laboratory Course Manual", 1996, CSHL PRESS
MIDTHUN DE. ET AL., MAYO CLIN PROC., vol. 72, 1997, pages 175
MORRISON VA. ET AL., AM J MED., vol. 97, 1994, pages 14
NGUYEN A ET AL., PLAST RECONSTR SURG., vol. 85, no. 3, 1990, pages 378 - 86
PERBAL, B., A PRACTICAL GUIDE TO MOLECULAR CLONING, 1984
PERBAL: "A Practical Guide to Molecular Cloning", 1988, JOHN WILEY & SONS
SALCEDO R ET AL., AM J PATHOL., vol. 154, no. 4, 1999, pages 1125 - 35
SAMBANIS, A.: "Encapsulated islets in diabetes treatment.", DIABETES THECHNOL. THER., vol. 5, 2003, pages 665 - 8
SAMBROOK ET AL., MOLECULAR CLONING: A LABORATORY MANUAL, 1989
SENDEROWICZ AM. ET AL., ANN INTERN MED., vol. 126, 1997, pages 882
SUTHANTHIRAN M., STROM TB., NEW ENGL. J. MED., vol. 331, 1996, pages 365
TATEISHI-YUYAMA E ET AL., LANCET, vol. 360, no. 9331, 2002, pages 427 - 35
TEPPER ET AL., CIRCULATION, vol. 106, 2002, pages 2781 - 6
THEVENOT P T ET AL: "The effect of incorporation of SDF-1@? into PLGA scaffolds on stem cell recruitment and the inflammatory response", BIOMATERIALS, vol. 31, no. 14, 1 May 2010 (2010-05-01), ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, pages 3997 - 4008, XP026947574, ISSN: 0142-9612, [retrieved on 20100224], DOI: 10.1016/J.BIOMATERIALS.2010.01.144 *
ULLMANN Y ET AL., DERMATOL SURG, vol. 31, 2005, pages 1304 - 7
ULUDAG, H. ET AL.: "Technology of mammalian cell encapsulation", ADV DRUG DELIV REV., vol. 42, 2000, pages 29 - 64, XP002302229, DOI: doi:10.1016/S0169-409X(00)00053-3
VINCENTI F. ET AL., NEW ENGL. J. MED., vol. 338, 1998, pages 161
WANG ET AL., J CELL BIOCHEM., vol. 103, no. 1, 2008, pages 21 - 9
WANG N ET AL: "Endothelial progenitor cells pre-cultured with stromal cell derived factor 1 alpha transplantation to treat hind limb ischemia in diabetic rats", ZHONGGUO ZUZHI GONGCHENG YU LINCHUANG KANGFU= JOURNAL OF CLINICAL REHABILITATIVE TISSUE ENGINEERING RESEARCH, ZHONGGUO KANGFU YIXUEHUI, CN, vol. 15, no. 36, 1 January 2011 (2011-01-01), pages 6749 - 6752, XP009154970, ISSN: 1673-8225 *
WATSON ET AL.: "Recombinant DNA", SCIENTIFIC AMERICAN
WILLIAMS D.: "Small is beautiful: microparticle and nanoparticle technology in medical devices", MED DEVICE TECHNOL., vol. 10, 1999, pages 6 - 9
YAMAGUCHI J. ET AL., CIRCULATION, vol. 107, no. 9, 2003, pages 1322 - 8
YAMAGUCHI J-I ET AL: "Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization", CIRCULATION, vol. 107, no. 9, 11 March 2003 (2003-03-11), LIPPINCOTT WILLIAMS & WILKINS, US, pages 1322 - 1328, XP002305134, ISSN: 0009-7322, DOI: 10.1161/01.CIR.0000055313.77510.22 *
YI ET AL., DERMATOL SURG., vol. 32, no. 12, 2006, pages 1437 - 43

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10639351B2 (en) 2013-10-22 2020-05-05 Helixmith Co., Ltd. Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor
WO2016048105A1 (fr) * 2014-09-26 2016-03-31 주식회사 바이로메드 Composition pour la prévention ou le traitement des maladies vasculaires périphériques utilisant le facteur de croissance des hépatocytes et le facteur 1α dérivé des cellules stromales
US11219667B2 (en) 2014-09-26 2022-01-11 Helixmith Co., Ltd. Method for treating peripheral vascular disease using hepatocyte growth factor and stromal cell derived factor 1A
WO2019070538A1 (fr) * 2017-10-03 2019-04-11 Wallkill BioPharma, Inc. Traitement du diabète avec des cellules bêta génétiquement modifiées
US10696950B2 (en) 2017-10-03 2020-06-30 Wallkill BioPharma, Inc. Treating diabetes with genetically modified beta cells
US10982190B2 (en) 2017-10-03 2021-04-20 Sdf Biopharma Inc. Genetically modified stem cells
US11186827B1 (en) 2017-10-03 2021-11-30 Sdf Biopharma Inc. Genetically modified stem cells
US11739298B2 (en) 2017-10-03 2023-08-29 Sdf Biopharma Inc. Genetically modified stem cells
US11981928B2 (en) 2018-09-28 2024-05-14 Sdf Biopharma Inc. Methods for reducing elevated glucose levels

Similar Documents

Publication Publication Date Title
Kaisang et al. Adipose-derived stem cells seeded in Pluronic F-127 hydrogel promotes diabetic wound healing
JP6871899B2 (ja) 補助的免疫抑制処置を行わないｍａｐｃ療法
US20200306319A1 (en) Methods for treating radiation or chemical injury
US20170290863A1 (en) Endometrial stem cells and methods of making and using same
US20140017209A1 (en) Methods for treating radiation or chemical injury
US11660317B2 (en) Compositions comprising cardiosphere-derived cells for use in cell therapy
JP6023864B2 (ja) 脂肪移植物の生存を増大させるための方法及び組成物
KR20160081994A (ko) 지방 또는 태반 조직 유래의 부착 세포 및 이의 치료 용도
BRPI0919020B1 (pt) Uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
ES2846795T3 (es) Células madres pluripotentes para el tratamiento de la úlcera cutánea diabética
Wang et al. Human acellular amniotic matrix with previously seeded umbilical cord mesenchymal stem cells restores endometrial function in a rat model of injury
Tracy et al. State of the field: cellular and exosomal therapeutic approaches in vascular regeneration
JP2022184911A (ja) 胎盤幹細胞を使用する糖尿病性足部潰瘍の治療
Chandra et al. Mesenchymal Stem Cells in Veterinary Regenerative Therapy: Basic Physiology and Clinical Applications
WO2012025925A1 (fr) Procédés d&#39;amélioration de la transplantation en utilisant des sdf-1alpha
Ignatov et al. Could human amniotic membrane be a source for acupoint thread embedding therapy?
JP2023513370A (ja) 線維芽細胞を用いた脳性麻痺の治療
Pacella et al. Stem cell therapy for brain injury in neonates
US20230203436A1 (en) High-potential pluripotent stem cells
Qin et al. Melatonin-pretreated human umbilical cord mesenchymal stem cells improved endometrium regeneration and fertility recovery through macrophage immunomodulation in rats with intrauterine adhesions
Tracy et al. New Developments in Translational Microcirculatory Research: State of the field: cellular and exosomal therapeutic approaches in vascular regeneration
Lavrentieva Strategies in umbilical cord-derived mesenchymal stem cells expansion
LeBlanc State of the Field: Cellular and Exosomal Therapeutic Approaches in Vascular Regeneration 2
KR20180051631A (ko) 태반 세포를 사용한 당뇨병성 말초 신경병증의 치료 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11767299

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11767299

Country of ref document: EP

Kind code of ref document: A1